Health Minister Greg Hunt has highlighted a number of new drugs to gain PBS listing
The new listings are worth $142 million, Mr Hunt says.
Vorinostat (Zolinza) will be available for the first time on the PBS to treat eligible patients with relapsed or refractory cutaneous T-cell Lymphoma, a subtype of non-Hodgkin’s lymphoma.
“Without government subsidy, this medicine would cost patients around $18,950 a year,” the Minister says.
“Also being listed is adalimumab (Humira) for the treatment of hidradentis suppurativa – an extremely painful, debilitating, inflammatory skin disease.
“This medicine would otherwise cost around $35,199 per course of treatment. Almost 400 patients will benefit.
“And for the treatment of idiopathic pulmonary fibrosis, pirfenidone (Esbriet) will be added to the PBS.
“IPF is characterised by the progressive deterioration of lung function and has debilitating effects on quality of life. The listing provides an additional treatment option for patients with this condition.”
Mr Hunt says that without subsidy, these medicines would be unaffordable for many Australians.
“Since coming into Government, we have added around $6 billion of new drugs to the Pharmaceutical Benefits Scheme,” he says, stating that “Labor delayed the listing of seven vital drugs”.
“The Turnbull Government has a rock solid commitment to Medicare and part of this commitment is ensuring people have access to medicine when they need it.”